Efficacy and Safety of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL

The purpose of this study is to compare the efficacy and safety of genotype-guided targeted agents in combination with polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola RCHP-X) versus Pola RCHP in Chinese patients with previously untreated diffuse large B-cell lymphoma (DLBCL).

Trial Details

NCT ID
NCT06803693
Phase
PHASE2
Sponsor
Ruijin Hospital
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • Polatuzumab vedotin
  • Rituximab
  • Cyclophosphamide
  • Doxorubicin
  • Prednisone
  • Zanubrutinib
Locations (sample)
  • Shanghai, Shanghai Municipality, China|31.22222,121.45806

Key Eligibility Criteria

  • Signed Informed Consent Form
  • Age 18-75 years at the time of signing Informed Consent Form and willingness to comply with study protocol procedures
  • Previously untreated participants with CD20-positive DLBCL
  • IPI score 2-5

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →